A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Segluromet
Synonyms :
ertugliflozin/metformin
Class :
Antidiabetics, SGLT2 Inhibitors; Antidiabetics, Biguanides
Brand Name :
Segluromet
Synonyms :
ertugliflozin/metformin
Class :
Antidiabetics, SGLT2 Inhibitors; Antidiabetics, Biguanides
Dosage Forms & StrengthsÂ
TabletÂ
2.5mg/1000mgÂ
7.5mg/1000mgÂ
2.5mg/500mgÂ
7.5mg/500mgÂ
Individualize the initial dose based on the patient's current regimen, but do not exceed 15 mg ertugliflozin and 2000 mg metformin daily.
Take twice a day along with the meals
Switching from ertugliflozin and/or metformin individually
Patients using metformin should switch to 2.5 mg ertugliflozin tablets, maintaining the exact metformin dosage throughout the day.
Patients on ertugliflozin: Switch to 500 mg metformin tablets with a comparable total daily dosage of ertugliflozin.
If you already use ertugliflozin and metformin, consider switching to tablets with the total daily dosage of ertugliflozin and a comparable daily metformin dose.
Dose Adjustments
Iodine-contrast imaging techniques
Patients with an 60 mL/min/1.73 m2 of eGFR , a history of liver disease, intoxication, or heart failure, or those who will receive intra-arterial iodinated contrast should discontinue iodinated contrast imaging at the time of or before the procedure.
48 hours after the imaging procedure, reevaluate eGFR; if renal function is stable, resume drug administration.
Renal impairment
eGFR 45 mL/min/1.73 m2: No dose change is required.
eGFR of 45 mL/min/1.73 m2: Not recommended.
End-stage renal disease, dialysis, or severe (eGFR 30 mL/min/1.73 m2):
Contraindicated
Hepatic impairment
Not advised.
Some lactic acidosis instances in people with hepatic impairment have been linked to metformin.
Safety and efficacy not establishedÂ
>65 years of age: Dosage adjustment is not neededÂ
may enhance the serum concentration of metformin
may enhance the serum concentration of metformin
may enhance the serum concentration of OCT2 substrates
may enhance the serum concentration of MATE1/2-K Substrates
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the adverse effect of metformin
may increase the adverse effect of metformin
may increase the adverse effect of metformin
may increase the adverse effect of metformin
may diminish the adverse effect of metformin
may enhance the serum concentration of metformin
may enhance the serum concentration of MATE1/2-K Substrates
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may enhance the serum concentration of MATE1/2-K Substrates
may enhance the serum concentration of metformin
may increase the hypoglycemic effect of Antidiabetic Agents
relugolix/​estradiol/​norethindrone
may increase the hypoglycemic effect of Antidiabetic Agents
relugolix/estradiol/norethindrone
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the hypoglycemic effect of Antidiabetic Agents
may decrease the therapeutic effect of Antidiabetic Agents
may decrease the therapeutic effect of Antidiabetic Agents
may decrease the therapeutic effect of Antidiabetic Agents
may decrease the therapeutic effect of Antidiabetic Agents
may decrease the therapeutic effect of Antidiabetic Agents
may decrease the therapeutic effect of Antidiabetic Agents
may decrease the therapeutic effect of Antidiabetic Agents
may decrease the anticoagulant effect of Vitamin K Antagonists
may decrease the anticoagulant effect of Vitamin K Antagonists
may decrease the anticoagulant effect of Vitamin K Antagonists
may decrease the anticoagulant effect of Vitamin K Antagonists
may decrease the anticoagulant effect of Vitamin K Antagonists
choline magnesium trisalicylate
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
Actions and Spectrum:Â
Mechanism of Action:Â
Spectrum of Activity:Â
The combination of ertugliflozin and metformin can result in improved glycemic control and additional benefits for patients with type 2 diabetes:Â
Glucose Lowering:Â Â
Weight Management:Â Â
Cardiovascular Benefits:Â Â
Frequency definedÂ
ertugliflozinÂ
>10%Â
Female genital mycotic infections (9.1-12.2%)Â
1-10% (ertugliflozin)Â
Male genital mycotic infections (3.7-4.2%)Â
Headache (2.9-3.5%)Â
Increased urination (2.4-2.7%)Â
Back pain (1.7-2.5%)Â
Weight decreased (1.2-2.4%)Â
Volume depletion adverse effects (1.9-4.4%)Â
Urinary tract infections (4-4.1%)Â
Vaginal pruritus (2.4-2.8%)Â
Nasopharyngitis (2-2.5%)Â
Renal adverse effects (1.3-2.5%)Â
Thirst (1.4-2.7%)Â Â
>5% (Metformin)Â
Initiating drugÂ
NauseaÂ
FlatulenceÂ
IndigestionÂ
HeadacheÂ
DiarrheaÂ
VomitingÂ
Abdominal discomfortÂ
AstheniaÂ
Long-term useÂ
Decreased absorption of vitamin B-12Â
Black box warning:Â
The potential for lactic acidosis necessitates a black box warning for both ertugliflozin and metformin. When persons take metformin with renal issues, lactic acidosis might develop.
The condition is characterized by increased blood lactic acid levels, which may have catastrophic consequences, including a fall in blood pH.Â
Contraindications/caution:Â
Contraindications:Â
ertugliflozin:Â
metformin:Â
Caution:Â
ertugliflozin:Â
metformin:Â
Pregnancy consideration:Â Â
ertugliflozin:Â
metformin:Â
Lactation: It is not known whether ertugliflozin is excreted in human milk.Â
metformin is excreted into breast milk but at relatively low levels.Â
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
DistributionÂ
Â
MetabolismÂ
Elimination and ExcretionÂ
Administration:Â
Oral administration:Â
Take everyday in the morning, with or without meals. Â
Dose missed Â
Use it immediately Â
You should not take a dosage if it is nearly time for your next scheduled dose.Â
Do not take two ertugliflozin dosages at the same time.Â
Patient information leafletÂ
Generic Name: ertugliflozin/metforminÂ
Why do we use ertugliflozin/metformin?Â
ertugliflozin and metformin are both medications used to treat type 2 diabetes mellitus. Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
